GSK - DNDi Collaboration

Partnership objective

Accelerate research into effective NTD treatments.

Patients urgently need better treatments for Leishmaniasis, Human African Trypanosomiasis and Chagas disease. Patients urgently need better treatments for Leishmaniasis, Human African Trypanosomiasis and Chagas disease. Copyright GSK

Description of partnership activities and how they address needs and challenges

In September 2013, GlaxoSmithKline (GSK) and Drugs for Neglected Diseases Initiative (DNDi) signed a two-year extension, with the possibility of an additional third year, of their current research collaboration agreement to develop new therapeutics for Leishmaniasis, Human African Trypanosomiasis and Chagas disease. Patients urgently need better treatments as the existing ones are not suitable due to the emergence of parasite resistance, their severe side effects and toxicity, costs or non-suitable routes of administration.

Under the terms of the agreement, DNDi and GSK will jointly exploit hits identified through GSK’s internal high throughput screening efforts vs. Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. DNDi will contribute with up to 12 chemistry FTEs from their own consortia in addition to the 2 matching FTEs at Tres Cantos. The scope of the agreement has been expanded to the identification of preclinical activities and will include testing of identified hit(s) in the corresponding animal models in order to evaluate their in vivo efficacy and further progression of efficacious compounds in Lead Optimization programs.

The partners will facilitate publication of the results to ensure access to the wider community of researchers focusing on NTDs. The public sector will benefit from the drugs developed through this agreement under the best possible conditions to ease access for patients in all endemic countries, irrespective of their level of economic development.

 



Partnership information

Company(ies) GlaxoSmithKline

Partner(s) Drugs for Neglected Diseases initiative (DNDi), London School of Hygiene and Tropical Medicine

Type of Partner(s) Academia / Hospitals, PDPs

Therapeutic Focus Neglected Tropical Diseases

Disease(s) Chagas Disease, Human African Trypanosomiasis (Sleeping Sickness), Leishmaniasis

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Research & Development - Development of Treatments, Research & Development - Pediatric R&D

Targeted Population(s) Marginalised / Indigenous People, Patients in needs of treatment, People with low income

Region(s) Europe & Central Asia, Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 85

Country(ies) Angola, Argentina, Bangladesh, Barbados, Belize, Benin, Bhutan, Bolivia, Botswana, Brazil, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Chile, Colombia, Comoros, Congo, Costa Rica, Côte d'Ivoire, Cuba, Democratic Republic of the Congo, Dominica, Dominican Republic, Ecuador, El Salvador, Equatorial Guinea, Eritrea, Ethiopia, French Guiana, Gabon, Ghana, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, India, Jamaica, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mexico, Mozambique, Namibia, Nepal, Nicaragua, Niger, Nigeria, Pakistan, Panama, Paraguay, Peru, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Swaziland, Tanzania, The Gambia, Togo, Trinidad and Tobago, Uganda, United Kingdom, Uruguay, Venezuela, Zambia, Zimbabwe

Start Date 2008

More information DNDi Screening

Anticipated completion date Ongoing